Entia Biosciences (ERGO) stock price, revenue, and financials

Entia Biosciences market cap is $279 k, and annual revenue was $265.47 k in FY 2016

$279 K

ERGO Mkt cap, 02-Oct-2018

$265.5 K

Entia Biosciences Revenue FY, 2016
Entia Biosciences Revenue growth (FY, 2015 - FY, 2016), %(23%)
Entia Biosciences Gross profit (FY, 2016)174 K
Entia Biosciences Gross profit margin (FY, 2016), %65.5%
Entia Biosciences Net income (FY, 2016)-1.4 M
Entia Biosciences EBIT (FY, 2016)-1.3 M
Entia Biosciences Cash, 31-Dec-201676.1 K
Entia Biosciences EV327.4 K

Entia Biosciences Revenue

Entia Biosciences revenue was $265.47 k in FY, 2016 which is a 23.5% year over year decrease from the previous period.

Embed Graph

Entia Biosciences Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

314.7k656.3k346.9k265.5k

Revenue growth, %

109%(47%)(23%)

Cost of goods sold

131.1k245.5k131.0k91.5k

Gross profit

183.6k410.9k215.9k174.0k

Gross profit Margin, %

58%63%62%66%

Sales and marketing expense

171.1k127.1k90.1k

General and administrative expense

1.6m1.5m1.4m960.0k

Operating expense total

3.2m1.5m2.2m1.5m

EBIT

(3.0m)(1.8m)(2.0m)(1.3m)

EBIT margin, %

(944%)(274%)(584%)(494%)

Interest expense

144.7k339.7k149.3k83.5k

Interest income

9.9k

Net Income

(3.1m)(2.3m)(2.3m)(1.4m)

Entia Biosciences Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

36.9k99.5k24.1k76.1k

Accounts Receivable

11.2k243.8k7.1k8.0k

Inventories

138.9k40.3k69.8k

Current Assets

225.5k484.7k128.3k234.3k

PP&E

62.1k43.1k32.7k18.3k

Total Assets

631.1k870.7k448.6k439.1k

Accounts Payable

1.2m569.2k960.6k1.4m

Short-term debt

23.8k51.0k39.1k62.2k

Current Liabilities

1.6m987.2k1.2m2.1m

Long-term debt

23.8k51.0k39.1k62.2k

Total Debt

47.6k102.1k78.1k124.4k

Total Liabilities

1.6m1.2m2.4m

Additional Paid-in Capital

7.8m10.8m12.3m12.5m

Retained Earnings

(8.5m)(10.8m)(13.1m)(14.5m)

Total Equity

(949.6k)(116.5k)(791.2k)(2.0m)

Debt to Equity Ratio

-0.1 x-0.9 x-0.1 x-0.1 x

Debt to Assets Ratio

0.1 x0.1 x0.2 x0.3 x

Financial Leverage

-0.7 x-7.5 x-0.6 x-0.2 x

Entia Biosciences Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(3.1m)(2.3m)(2.3m)(1.4m)

Depreciation and Amortization

36.0k32.0k17.7k

Accounts Receivable

(30.7k)(262.6k)236.7k(875.0)

Inventories

(15.8k)43.6k53.025.6k

Accounts Payable

661.2k766.1k553.8k412.9k

Cash From Operating Activities

(766.7k)(680.3k)(536.6k)(715.1k)

Purchases of PP&E

(52.5k)(4.6k)(8.1k)

Cash From Investing Activities

(64.6k)(45.5k)(21.3k)(7.1k)

Cash From Financing Activities

855.1k788.3k482.5k774.1k

Interest Paid

1.1k843.037.8k6.7k

Quarterly

Entia Biosciences Ratios

USDY, 2016

EV/EBIT

-0.2 x

EV/CFO

-0.5 x

Revenue/Employee

22.1k

Debt/Equity

-0.1 x

Debt/Assets

0.3 x

Financial Leverage

-0.2 x